// App-Quantinova.ai

TPS4152 : POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).

Researchers

Presenter

  • Talia Golan

Principal Investigators

  • Do-Youn Oh

  • Michele Reni

  • Teresa Mercade Macarulla

  • Giampaolo Tortora

  • Michael J. Hall

  • Anke C. Reinacher-Schick

  • Christophe Borg

  • Daniel Hochhauser

  • Thomas Walter

  • Howard S. Hochster

  • Nigel Baker

  • Gershon Y. Locker

  • Hedy L. Kindler

Medical Centers

  • The Oncology Institute Sheba Medical Center, Tel-Hashomer, Israel

  • Hospital San Raffaele, Milan, Italy

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Medical School and University Hospital, Verona, Italy

  • Fox Chase Cancer Center, Philadelphia, PA

  • St. Josef-Hospital, Klinikum der Ruhr-Universitat Bochum, Bochum, Germany

  • Hopital Jean Minjoz, Besancon, France

  • UCL Cancer Institute, University College London,, London, United Kingdom

  • Edouard Herriot Hospital, Lyon, France

  • Yale New Haven Hospital, New Haven, CT

  • AstraZeneca, Gaithersburg, MD

  • The University of Chicago Medical Center, Chicago, IL

Locations

  • Italy

  • Spain

  • Germany

  • United Kingdom

  • United States

  • Israel

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Metastatic pancreatic adenocarcinoma

Biomarkers

  • Breast cancer type 1 susceptibility protein

Drug/Treatment

  • Olaparib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT01078662

  • NCT02184195

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved